The Goldman Sachs Group Upgrades Tempus AI (NASDAQ:TEM) to Hold

Tempus AI (NASDAQ:TEM) was upgraded by equities researchers at The Goldman Sachs Group to a “hold” rating in a report issued on Monday, Zacks reports.

TEM has been the subject of a number of other reports. Rothschild & Co Redburn began coverage on Tempus AI in a research report on Tuesday, September 8th. They issued a “neutral” rating and a $67.00 price objective for the company. UBS Group started coverage on Tempus AI in a report on Wednesday, September 9th. They set a “neutral” rating and a $70.00 target price on the stock. HC Wainwright increased their price target on Tempus AI from $56.00 to $66.00 and gave the company a “buy” rating in a research note on Friday, September 11th. Wall Street Zen raised Tempus AI from a “sell” rating to a “hold” rating in a report on Saturday, July 25th. Finally, Piper Sandler raised shares of Tempus AI from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $56.00 to $76.00 in a research report on Tuesday, September 1st. Eleven analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $69.63.

Tempus AI Stock Up 0.2%

Tempus AI stock opened at $78.03 on Monday. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. The company’s 50-day moving average is $57.63 and its 200-day moving average is $53.09. The firm has a market capitalization of $14.08 billion, a PE ratio of -54.19 and a beta of 3.72. Tempus AI has a fifty-two week low of $40.77 and a fifty-two week high of $104.32.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The business had revenue of $382.49 million during the quarter, compared to the consensus estimate of $379.69 million. During the same period last year, the business posted ($0.22) EPS. Tempus AI’s revenue was up 21.6% on a year-over-year basis. Sell-side analysts anticipate that Tempus AI will post -1.38 earnings per share for the current year.

Insider Activity

In other news, Director Nadja West sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $69.00, for a total transaction of $207,000.00. Following the completion of the sale, the director owned 31,981 shares in the company, valued at $2,206,689. The trade was a 8.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Polovin sold 2,951 shares of the company’s stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $75.00, for a total value of $221,325.00. Following the completion of the transaction, the executive vice president directly owned 135,189 shares in the company, valued at $10,139,175. The trade was a 2.14% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 1,254,701 shares of company stock valued at $73,877,392. Company insiders own 24.26% of the company’s stock.

Institutional Investors Weigh In On Tempus AI

Hedge funds and other institutional investors have recently modified their holdings of the company. Eagle Health Investments LP bought a new position in Tempus AI during the 1st quarter worth $11,588,000. Alethea Capital Management LLC bought a new stake in shares of Tempus AI during the 4th quarter valued at $1,863,000. Aristotle Atlantic Partners LLC acquired a new stake in shares of Tempus AI during the 1st quarter worth $6,179,000. Headlands Technologies LLC acquired a new stake in shares of Tempus AI during the 2nd quarter worth $2,689,000. Finally, Lingotto Investment Management LLP increased its position in shares of Tempus AI by 45.9% in the fourth quarter. Lingotto Investment Management LLP now owns 1,143,526 shares of the company’s stock worth $67,525,000 after purchasing an additional 359,667 shares during the period. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI News Summary

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Operating growth supports the bullish case. Tempus AI’s oncology testing volumes increased 31% year over year in the second quarter, while minimal residual disease testing volumes have nearly doubled since the fourth quarter of 2025. The data and applications segment grew 28%, supported by bookings and AI innovation, potentially improving long-term revenue growth and margins. Tempus AI: Data And Applications Will Unlock More Upside
• Positive Sentiment: Expanded strategic partnerships could strengthen its data business. Tempus AI and Recursion extended their data license agreement and amended the fee structure, signaling continued commercial use of Tempus’s healthcare data and potentially supporting recurring data-related revenue. Tempus AI, Recursion Extend Data License, Amend Fee Structure
• Positive Sentiment: Government-backed AI development adds a growth option. ARPA-H selected Tempus to develop an autonomous AI agent for heart-failure care, with funding of up to $9.5 million. Although modest relative to the company’s quarterly sales, the project could enhance Tempus’s credibility in clinical AI and expand its addressable market. Tempus Secures Up To $9.5 Million From ARPA-H
• Neutral Sentiment: Analyst coverage is cautious. Goldman Sachs initiated Tempus AI at a Neutral rating with a $75 price target, suggesting limited near-term upside after the stock’s recent advance. Goldman Sachs Initiates Tempus AI at Neutral
• Negative Sentiment: Insider selling may weigh on sentiment. Tempus executives, including the CEO, EVP, and chief accounting officer, sold shares in transactions ranging from approximately $221,000 to $16.1 million. These sales do not necessarily indicate deteriorating fundamentals, but they can raise concerns about valuation and near-term supply.
• Negative Sentiment: Valuation remains a key risk. Critical commentary argues that the market may be pricing in uncertain future growth too aggressively, particularly after the recent 60% rally. Tempus AI: Market Is Hyping On An Uncertain Number

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company focused on applying artificial intelligence and data analytics to precision medicine. The company combines molecular testing, clinical data and machine learning to help physicians make more informed treatment decisions and support the development of new therapies.

Tempus provides genomic and diagnostic testing services, including testing intended to identify clinically relevant mutations and other biomarkers. Its technology platform also organizes and analyzes clinical and molecular data, while its AI-enabled tools are designed to assist healthcare professionals with patient care, research and workflow management.

The company serves healthcare providers, patients, pharmaceutical companies and biotechnology researchers, primarily in the United States.